Rapid target engagement of KRAS G12C tricomplex inhibitor RO3903 overcomes resistance and drives durable tumor regression
Proceedings of the National Academy of Sciences, Volume 123, Issue 45, November 2026. SignificanceTransient target coverage enables oncogenic variants to cycle into drug-insensitive conformations, fueling adaptive resistance in precision oncology.